Brighton Jones’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$227K Buy
10,550
+5
+0% +$124 ﹤0.01% 1207
2026
Q2
$223K Sell
10,545
-28
-0.3% -$599 ﹤0.01% 1199
2026
Q1
$231K Buy
+10,573
New +$235K 0.01% 1029
2025
Q4
– Sell
-10,513
Closed -$123K – 480
2025
Q3
$123K Buy
10,513
+22
+0.2% +$219 ﹤0.01% 985
2025
Q2
$97.6K Buy
+10,491
New +$86K ﹤0.01% 890
2024
Q2
– Sell
-8,477
Closed -$209K – 652
2024
Q1
$209K Buy
+8,477
New +$172K 0.01% 565

Other funds holding IMNM

Brighton Jones's IMNM Position: Q3 2026 in Review

Brighton Jones increased its Immunome (IMNM) stake by 0.05% in Q3 2026, buying an estimated $124 and bringing the position to 10,550 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #1207.

Brighton Jones first reported a position in IMNM in Q1 2024 and has held it in 6 quarters since. The position peaked at $231K in Q1 2026. 163 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

  • Brighton Jones held 10,550 shares of Immunome worth $227K as of Q3 2026.
  • Brighton Jones bought 5 Immunome shares in Q3 2026, an estimated $124.
  • Immunome made up ﹤0.01% of Brighton Jones's portfolio in Q3 2026, its #1207 holding.
  • Brighton Jones first reported a position in Immunome in Q1 2024 and has held it in 6 quarters since.
  • Brighton Jones's Immunome position peaked at $231K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.